BioScience Laboratories
Bozeman, Montana, 59715, United States
NCT Number: NCT00636480
Determine the antimicrobial properties of a proposed new product and an already approved product and a placebo (no drug). Study will be conducted using methods dictated by the FDA.
Looking for future studies?
Notify Me16 year and older
All sexes
Interventional
Phase 3
Bozeman, Montana, 59715, United States
Determine the antimicrobial properties of a proposed new product and an already approved product and a placebo (no drug). Study will be conducted using methods dictated by the FDA.
This study uses topical sampling from the abdomen and the groin on intact skin and evaluates the germs left on the skin after treatment with the proposed new product, the currently approved product and the placebo.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
Other names: ChloraPrep AQ
Administer topically
Other names: Chlorhexidine gluconate 2% w/v and 70% v/v isopropyl alcohol
0.9% NaCl solution
Other names: Physiologic saline (0.9% NaCl)
Time frame: 10 minutes and 6 hours after application of test solutions
C. R. Bard
Industry
Preoperative Skin Preparation Evaluation of One Test Product With a Positive and a Negative Control
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00799812
Topical Antisepsis
Sterling, Virginia, United States
View Trial Details